Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CXB909 in Healthy Male Volunteers
NCT01505907Phase 2Unknown
- Sponsor
- CeNeRx BioPharma
- Start
- Dec 2012
- Primary completion
- Dec 2013
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of CXB909 in chemotherapy-induced peripheral neuropathy (CIPN) and Alzheimer's disease (AD) (6 arms), sponsored by CeNeRx BioPharma. Primary endpoint: Pharmacokinetic Parameters at 1 week. Status: unknown.
02
Drugs
CXB909
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01505907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505907.